The proportion of CD8+ T cells in B16F1-βA melanoma grafts also increased if they expressed Klk8 shRNA, relative to shKlk8-expressing B16F1-Ctrl tumors, and a similar trend was seen relative to βA tumors expressing shLuc or no shRNA (Fig. S5B). These data suggest that shKlk8 specifically alters the function of Activin-A. Here, KLK8 is linked to melanoma.